Johnson & Johnson’s Protagonist-partnered oral psoriasis candidate was able to sustain its therapeutic benefit through one year, according to data presented on Saturday at the American Academy of Dermatology annual meeting.
Fresh off its $259 million Series C funding round, Alumis unveiled mid-stage data Saturday for its TYK2 inhibitor ESK-001 demonstrating strong symptomatic improvement in moderate-to-severe plaque psoriasis.
Over the weekend, at the American Academy of Dermatology annual meeting, Novartis revealed early Phase IIb data from 66 patients who had been treated with either 25 mg or 100 mg of remibrutinib, which was dosed twice-daily.
The country is upping its specialized teams tasked with responding to future infectious disease outbreaks from five to 25.
Eli Lilly announced late-breaking results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
The CEO of the world’s biggest vaccine maker, Serum Institute of India, said the company has bolstered its manufacturing ahead of launches over the next few years of shots against diseases like malaria and dengue by repurposing facilities used to make COVID-19 immunizations.
The Danish drugmaker hopes to develop amycretin in its oral and injectable form simultaneously.
Novo Nordisk said early trial data for its highly anticipated experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment, sending its shares to new record highs.
A study showed GSK’s experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a potential comeback for the drug after several setbacks.
Sionna Therapeutics announced it raised another round of funding as the company looks to challenge Vertex Pharmaceuticals’ dominant cystic fibrosis business.
